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Abstract
Reduced circulating natriuretic peptide concentrations are independently associated with insulin resistance and type 2
diabetes, while increased natriuretic peptide levels appear to be protective. Observations in vitro and in heart failure
patients suggest that atrial natriuretic peptide (ANP) promotes adiponectin release, an adipokine with insulin sensitizing
properties. We tested the hypothesis that ANP acutely raises adiponectin levels in 12 healthy men. We infused ANP
intravenously over 135 minutes while collecting venous blood and adipose tissue microdialysates at baseline and at the end
of ANP-infusion. We obtained blood samples at identical time-points without ANP infusion in 7 age and BMI matched men.
With infusion, venous ANP concentrations increased ,10 fold. Systemic and adipose tissue glycerol concentrations
increased 70% and 80%, respectively (P,0.01). ANP infusion increased total adiponectin 1465% and high molecular-weight
(HMW)-adiponectin 1365% (P,0.05). Adiponectin did not change in the control group (P,0.05 vs. infusion). ANP-induced
changes in HMW adiponectin and adipose tissue lipolysis were directly correlated with each other, possibly suggesting
a common mechanism. Our data show that ANP acutely increases systemic total and HMW-adiponectin concentrations in
healthy subjects. Our study could have implications for the physiological regulation of adiponectin and for disease states
associated with altered natriuretic peptide availability.
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Introduction
Reduced circulating natriuretic peptide concentrations are
independently associated with insulin resistance and type 2
diabetes [1–3]. In contrast, augmented natriuretic peptide
availability improves insulin sensitivity in mice [4]. Furthermore,
genetic polymorphisms in the promoter region of the brain
natriuretic peptide (BNP) gene are associated with increased BNP
levels while protecting from type 2 diabetes [5]. How chronic
changes in natriuretic peptides could affect glucose homeostasis in
man is not understood. Atrial natriuretic peptide (ANP) and BNP
effects on blood pressure and volume regulation have been
extensively studied. However, natriuretic peptides also regulate
adipose tissue metabolism. ANP and BNP induced natriuretic
peptide receptor A activation potently stimulates adipose tissue
lipolysis through cGMP and protein kinase G activation [6,7]. The
mechanism cannot explain protective natriuretic peptide influ-
ences on glucose metabolism. Instead, natriuretic peptide may
promote adiponectin production, an adipokine with insulin
sensitizing properties. ANP augmented adiponectin production
and release from cultured human adipocytes [8]. In heart failure
patients, therapeutic ANP infusions increased total and high
molecular weight (HMW) adiponectin levels [9]. Studies in heart
failure patients could be confounded by the underlying pathology.
The heart failure-associated neurohumoral activation may be
particularly important in this regard. Heart failure medications
including beta-adrenoreceptor blockers and renin-angiotensin-
aldosterone system inhibitors could also affect natriuretic peptide
mediated responses. Therefore, we tested the hypothesis that ANP
acutely increases adiponectin levels in healthy men.
Methods
The local ethics committee approved the study and written-
informed consent was obtained. We included 12 healthy men
(3062 years, 24.160.5 kg/m2) receiving no medications. After an
overnight fast, we placed one catheter each into large antecubital
veins of both arms. We used one catheter for infusion and the
other one for blood sampling. We inserted a microdialysis probe
(CMA/60 microdialysis catheters, Solna, Sweden, cut off 30 kDa)
into abdominal subcutaneous adipose tissue to monitor changes in
tissue lipolysis and blood flow (ethanol dilution). After at least
60 min resting phase, an incremental administration of human
ANP (hANP) with a maximal rate of 25 ng/kg/min and a total
infusion time of 135 min commenced as described previously [7]
while blood pressure was closely monitored. ANP concentrations
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were determined using a radioimmunoassay. Total and HMW-
adiponectin plasma concentrations were measured using multi-
meric ELISA. We monitored ANP-induced changes in adipocyte
lipolysis through plasma and microdialysate glycerol measure-
ments. To exclude a time effect, we also obtained venous blood
samples in 7 healthy age and BMI-matched men (age 3364 years,
BMI 2461 kg/m2) at identical time points without ANP infusion.
Two tailed, one sample t-test and linear regression analysis were
used to compare changes in adiponectin with ANP infusion and to
establish associations between ANP, adiponectin and metabolic
parameters, respectively. Changes between groups were compared
by student’s t-test. Data are expressed as mean6SEM.
Results
Plasma ANP was 4165 pg/mL at baseline and increased to
447629 pg/mL at the end of the ANP infusion (P,0.01, data not
shown). During ANP infusion, systolic blood pressure decreased
from 11663 mm Hg at baseline to 11062 mm Hg at the end of
ANP infusion (P,0.05). Diastolic blood pressure was 6262 mm
Hg at baseline and did not change significantly with ANP infusion
(data not shown). Venous glycerol concentration increased from
4865 mmol/L at baseline to 81680 mmol/L with ANP infusion
(P,0.01). Dialysate glycerol in adipose tissue increased from
5166 mmol/L at baseline to 90614 mmol/L with ANP infusion
(p,0.01, figure 1) while the ethanol ratio did not change. Thus,
ANP was sufficiently dosed to affect adipose tissue function. Total
adiponectin was 5.660.5 pg/ml at baseline and increased by
1465% (6.360.5 pg/ml, 95% CI from 2 to 25%, P,0.05) with
ANP infusion (figure 1). HMW-adiponectin, the most potent
isoform in terms of insulin sensitization, was 2.960.3 pg/ml at
baseline and increased by 1365% (3.4960.4 pg/ml, 95% CI from
2 to 24%, P,0.05) with ANP (figure 1). The change in HMW-
adiponectin was directly correlated with the change in plasma
ANP with ANP infusion (r2 = 0.35, P= 0.05, figure 1). Changes in
adipose tissue glycerol and HMW-adiponectin with ANP infusion
also showed a positive correlation (r2 = 0.37, P,0.05, figure 1). In
the control group, total adiponectin and HMW-adiponectin were
reduced by 462% and 961%, respectively (ns), and the response
was attenuated compared to the intervention group (P= 0.06 for
total adipoenctin, P,0.05 for HMW-adiponectin).
To gain insight in mechanisms contributing to ANP-induced
adiponectin regulation, we compared 4 subjects with the lowest
adiponectin response (‘‘non-responsive’’) to the remaining 8
subjects (‘‘responsive’’) from the ANP treated group (figure 1 -
panel A). We did not observe differences for ANP concentrations,
glycerol plasma or dialysate concentrations as well as plasma free
fatty acid-, norepinephrine or epinephrine concentrations (data
not shown) between subgroups. However, waist circumference,
reflecting intraabdominal fat mass, was 8562 cm in the responsive
and 9162 in the non-responsive group (P= 0.056).
Discussion
The main finding of our study is that ANP acutely increases
systemic total and HMW-adiponectin concentrations in healthy
subjects. Our study also suggests that ANP raises adiponectin in
a concentration dependent fashion. The correlation between ANP
induced adipose tissue lipolysis and adiponectin release might
suggest a common transduction mechanism for both, lipase
activation and adiponectin release involving adipocyte NPR-A
receptors with subsequent cGMP generation. Our data is further
supported by in vitro experiments in cultured human adipocytes
showing that ANP dose-dependently enhanced the expression of
adiponectin mRNA and its secretion from adipocytes [8].
However, we cannot completely rule out the possibility that
ANP also altered renal or hepatic adiponectin clearance [10]. Our
study could have implications for the regulation of adiponectin in
conditions with altered natriuretic peptide availability. For in-
stance, natriuretic peptides could mediate their effect on glucose
metabolism through adiponectin, at least in a chronic setting,
while acute ANP infusion did not result in an increase in insulin
sensitivity [11]. Adiponectin is known to signal via the activation of
AMP-activated protein kinase (AMPK). ANP has recently been
shown to also activate AMPK in adipocytes [12]. We dare to
suggest that natriuretic peptides might induce AMPK through
adiponectin release.
Previous studies in heart failure patients showed that therapeutic
ANP infusions for 3 days increased total and high molecular
weight (HMW) adiponectin levels [9]. Patients with heart failure
are characterized by specific traits: First, they have increased
sympathetic nervous activity. Second, they have a whole range of
co-morbidities, such as renal insufficiency and changes in body
composition that interfere with natriuretic peptide levels, and
finally, they receive different medications, such as beta-adrenergic
receptor blockers, which also influence natriuretic peptide levels.
The most important confounder in this regard is increased
sympathetic nervous activity. Adipocyte stimulation with beta
adrenergic receptor agonists potently reduced adiponectin expres-
sion and release [13]. The inhibitory response was almost
completely reversed by non selective beta-adrenoreceptor block-
ade [13]. Natriuretic peptides reduce sympathetic nervous activity
and the effect is more pronounced in heart failure patients
compared to healthy controls [14]. Thus, in heart failure patients,
adiponectin induction through natriuretic peptides could be in
part explained by sympathetic inhibition, abolishing the inhibitory
effect on adiponectin transcription and secretion. We have
previously shown that the infusion of ANP in healthy lean subjects
did not affect sympathetic nervous activity, and that ANP’s
metabolic action in healthy subjects are not mediated through
sympathetic mechanisms [15].
Plasma adiponectin as well as ANP concentrations are reduced
in conditions associated with obesity [16]. Our preliminary
subgroup analysis suggests that subjects with increased waist
circumference, reflecting increased abdominal adiposity, might be
less responsive to adiponectin induction through ANP. Indeed,
increased adiposity is associated with reduced natriuretic peptide
availability likely through increased clearance secondary to NPR-
C scavenger receptor up-regulation in adipose tissue [17,18].
Decreased natriuretic peptide availability at the adipose tissue level
may promote adiponectin deficiency in this setting.
Paradoxically, increased adiponectin concentrations in heart
failure and patients with myocardial infarction independently
predict all cause and cardiovascular mortality [19]. Pathophysi-
ological conditions including heart failure are associated with
excessive ANP concentrations, which can increase up to levels as
high as 500 pg/mL. Therefore, the levels induced in our study are
of clinical relevance. We [20] and others [21] have shown that in
heart failure patients, adipose tissue does not seem to desensitize
towards metabolic natriuretic peptide actions. Thus, natriuretic
peptides could chronically raise adiponectin concentrations,
particularly in severely affected heart failure patients. The
mechanisms could explain the counterintuitive direct relationship
between adiponectin levels and mortality in cardiac patients. We
conclude that natriuretic peptides modulate systemic adiponectin
concentrations in young healthy individuals, thus, providing a link
between cardiac function, volume status, and lipid and glucose
metabolism.
ANP and Adiponectin
PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e43238
Acknowledgments
We thank Dr. Max Lafontan for help with the interpretation of the data.
Author Contributions
Conceived and designed the experiments: ALB MB FCL JJ. Performed the
experiments: AB MB CM. Analyzed the data: AB MB SE AA JJ.
Contributed reagents/materials/analysis tools: AA. Wrote the paper: AB
CM SE AA FCL JJ.
References
1. Khan AM, Cheng S, Magnusson M, Larson MG, Newton-Cheh C, et al. (2011)
Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two
community-based studies. J Clin Endocrinol Metab 96: 3242–3249.
2. Magnusson M, Jujic A, Hedblad B, Engstrom G, Persson M, et al. (2011) Low
Plasma Level of Atrial Natriuretic Peptide Predicts Development of Diabetes:
The Prospective Malmo Diet and Cancer Study. J Clin Endocrinol Metab.
3. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, et al. (2007)
Association of plasma natriuretic peptide levels with metabolic risk factors in
ambulatory individuals. Circulation 115: 1345–1353.
4. Miyashita K, Itoh H, Tsujimoto H, Tamura N, Fukunaga Y, et al. (2009)
Natriuretic peptides/cGMP/cGMP-dependent protein kinase cascades promote
muscle mitochondrial biogenesis and prevent obesity. Diabetes 58: 2880–2892.
5. Meirhaeghe A, Sandhu MS, McCarthy MI, de GeP, Cottel D, et al. (2007)
Association between the T-381C polymorphism of the brain natriuretic peptide
gene and risk of type 2 diabetes in human populations. Hum Mol Genet 16:
1343–1350.
6. Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, et al. (2008) Control
of lipolysis by natriuretic peptides and cyclic GMP. Trends Endocrinol Metab
19: 130–137.
7. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, et al. (2005) Lipid
Mobilization with Physiological Atrial Natriuretic Peptide Concentrations in
Humans. J Clin Endocrinol Metab 90: 3622–3628.
8. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, et al. (2009) Natriuretic
peptides enhance the production of adiponectin in human adipocytes and in
patients with chronic heart failure. J Am Coll Cardiol 53: 2070–2077.
9. Ohara T, Hashimura K, Asakura M, Ogai A, Amaki M, et al. (2011) Dynamic
changes in plasma total and high molecular weight adiponectin levels in acute
heart failure. J Cardiol 58: 181–190.
10. Halberg N, Schraw TD, Wang ZV, Kim JY, Yi J, et al. (2009) Systemic fate of
the adipocyte-derived factor adiponectin. Diabetes 58: 1961–1970.
11. Birkenfeld AL, Budziarek P, Boschmann M, Moro C, Adams F, et al. (2008)
Atrial natriuretic peptide induces postprandial lipid oxidation in humans.
Diabetes 57: 3199–3204.
12. Souza SC, Chau MD, Yang Q, Gauthier MS, Clairmont KB, et al. (2011) Atrial
natriuretic peptide regulates lipid mobilization and oxygen consumption in
human adipocytes by activating AMPK. Biochem Biophys Res Commun 410:
398–403.
13. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Adiponectin
gene expression is inhibited by beta-adrenergic stimulation via protein kinase A
in 3T3-L1 adipocytes. FEBS Lett 507: 142–146.
14. Brunner-La Rocca HP, Kaye DM, Woods RL, Hastings J, Esler MD (2001)
Effects of intravenous brain natriuretic peptide on regional sympathetic activity
in patients with chronic heart failure as compared with healthy control subjects.
J Am Coll Cardiol 37: 1221–1227.
15. Birkenfeld AL, Boschmann M, Moro C, Adams F, Heusser K, et al. (2006) Beta-
Adrenergic and Atrial Natriuretic Peptide Interactions on Human Cardiovas-
cular and Metabolic Regulation. J Clin Endocrinol Metab 91: 5069–5075.
16. Scherer PE (2006) Adipose tissue: from lipid storage compartment to endocrine
organ. Diabetes 55: 1537–1545.
Figure 1. ANP induces total and HMW-adiponectin. A – Individual changes in venous total as well as HMW-adiponectin with ANP infusion. The
bar indicates the mean value (P = compared to baseline, n = 12). B – Correlation between the change in plasma ANP and the change in HMW
adiponectin with ANP infusion (n = 11). C – Individual changes in dialysate glycerol in subcutaneous adipose tissue (SCAT) with ANP infusion. The bar
indicates the mean value (P = compared to baseline, n = 11). D - Correlation between D SCAT dialysate glycerol, a marker for lipolysis, and the change
in HMW adiponectin with ANP infusion (n = 11).
doi:10.1371/journal.pone.0043238.g001
ANP and Adiponectin
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e43238
17. Sarzani R, Dessi-Fulgheri P, Paci VM, Espinosa E, Rappelli A (1996) Expression
of natriuretic peptide receptors in human adipose and other tissues. J Endocrinol
Invest 19: 581–585.
18. Nakatsuji H, Maeda N, Hibuse T, Hiuge A, Hirata A, et al. (2010) Reciprocal
regulation of natriuretic peptide receptors by insulin in adipose cells. Biochem
Biophys Res Commun 392: 100–105.
19. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, et al. (2005) Plasma
adiponectin, body mass index, and mortality in patients with chronic heart
failure. Circulation 112: 1756–1762.
20. Birkenfeld AL, Adams F, Schroeder C, Engeli S, Jordan J (2011) Metabolic
actions could confound advantageous effects of combined angiotensin II receptor
and neprilysin inhibition. Hypertension 57: e4-e5.
21. Polak J, Kotrc M, Wedellova Z, Jabor A, Malek I, et al. (2011) Lipolytic effects of
B-type natriuretic peptide 1–32 in adipose tissue of heart failure patients
compared with healthy controls. J Am Coll Cardiol 58: 1119–1125.
ANP and Adiponectin
PLOS ONE | www.plosone.org 4 August 2012 | Volume 7 | Issue 8 | e43238
